Pertuzumab
帕捷特(Perjeta)
A second HER2 antibody used together with trastuzumab for a deeper blockade.
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
In NRDL.
Regulatory status
NMPA approved (2018); NRDL (2022)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
HER2-positive breast cancer: neoadjuvant, adjuvant and metastatic, with trastuzumab.
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Pertuzumab. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.